Mankind Pharma Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mankind Pharma Ltd.
Boehringer Ingelheim tackles infringement activity pertaining to Trajenta and Jardiance in India, at least for now, but more action appears to be in the wings. The private German group remains confident that Jardiance will retain its preferred treatment choice status in the country for type 2 diabetes - but can the blockbuster therapy shake up the heart failure segment as well?
German firm’s antibody-drug conjugates use amanitin payload. Plus deals involving Sanwa Kagaku/Crinetics, Takeda/Code Bio, Taro/Alchemee, Mankind/Dr. Reddy’s and more.
Novartis CEO Vas Narasimhan has told Scrip that the company is “aggressively defending each group of patents” on its cardiovascular blockbuster which topped the $900m sales mark in the fourth quarter.
Mankind Pharma has licensed Novartis’ heart failure therapy Entresto in India, executive chairman Ramesh Juneja tells Scrip. The privately-owned company has also acquired the generics business of Panacea in India and Nepal for over $255m.